Volume 13, Number 1, 36-42, DOI: 10.1007/s12199-007-0001-1

Published in partnership with

Logo

Association of serum NO x level with clustering of metabolic syndrome components in middle-aged and elderly general populations in Japan

Jun Ueyama, Takaaki Kondo, Ryota Imai, Akiko Kimata, Kanami Yamamoto, Koji Suzuki, Takashi Inoue, Yoshinori Ito, Ken-ichi Miyamoto and Takaaki Hasegawa, et al.

View Related Documents

Abstract

Objectives  

The aim of this study was to determine whether the serum nitrite plus nitrate (NO x ) level correlates with biomarkers that are known components of the metabolic syndrome (MetS).

Methods  

Serum NO x levels were measured using a commercial kit in 608 Japanese men and women between the ages of 39 and 85 years. Multivariate adjustments for age, smoking status, alcohol consumption and exercise were made in the analysis of covariance (ANCOVA). The components of the metabolic syndrome were defined based on the following criteria: body mass index (BMI) ≥25.0 kg/m2, glycated hemoglobin (HbA1c) ≥5.6%, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, high-density lipoprotein-cholesterol (HDL-C) ≤1.03 mmol/l for men and ≤1.29 mmol/l for women and triglyceride ≥1.69 mmol/l.

Results  

The logarithmically transformed age-adjusted serum NO x (lnNO x ) value was significantly higher in the low HDL-C group (1.76 ± 0.05 μmol/l; p < 0.05) than MetS component groups (1.65 ± 0.01 μmol/l) in men, but no difference was found in women. The means of serum lnNO x after multivariate adjustment were 1.64, 1.65, 1.64, 1.66, and 1.81 μmol/l for 0, 1, 2, 3, and 4–5 MetS components for all subjects, respectively. The results of ANCOVA confirmed that the serum lnNO x level was significantly correlated with the clustering of MetS components in both men and women (p < 0.0001 for trend).

Conclusion  

Our results suggest that an increase in the clustering of MetS components was associated with the increase in serum NO levels in our general population.

Keywords  Analysis of covariance - Cyclic guanosine 3′5′-Monophosphate (cGMP) - Metabolic syndrome - Nitric oxide

Fulltext Preview

Image of the first page of the fulltext document